6Hammer SM,Squires KE, Hughes MD,et al. A controlled trial of two nucledoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [ J ]. N Engl JMed, 1997, 337(11) :725.
7San-Andres FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportun- istic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997[J]. Clin Infect Dis, 2003, 36(9) :1177.
8Clave1 F. HIV resistance to raltegravir [ J]. Eur J Med Res ,2009,14( Suppl 3 ) :47.
9Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Rea- sons for modification of generic highly active antiretroviral therapeutic regimens among [ J]. J Acquit Immune Defic patients in southern India Syndr, 2006, 41 ( 1 ) :53.
10Aghokeng AF, Kouanfack C, Laurent C, et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accom- panied by increasing HIV-1 drug resistance mutations in drug-naive patients [J]. AIDS, 2011, 25(17):2183.
